TRIALS @HOME

CLOSING EVENT

Trials@Home, a home run?

Recommendations after leading the way on DCTs in Europe

31 October, 2025

Spoorwegmuseum
Maliebaan station 16

Utrecht

Questions?

If you have any questions, you're welcome to approach one of our event managers, Annemarijn and Ashton, or send an e-mail to trialsathome@umcutrecht.nl.

Annemarijn Douwes

Ashton Babcock

TRIALS @HOME

Table of contents

Agenda at-a-glance

08:30- 09:00	Coffee
09:00 - 09:15	Welcome
09:15 - 10:45	Trials@Home key final recommendations
10:45 - 11:15	Coffee & Poster Gallery
11:15 - 12:15	Trials@Home deep dive (short presentations)
12:15 - 12:20	Group photo
12:20 - 13:45	Lunch & networking
13:45 - 14:55	Impact in the DCT field
14:55 - 15:25	Coffee & poster gallery
15:25 - 16:55	The future of DCTs
16:55 - 17:00	Wrap-up
17:00 - 18:00	Drinks




CONVENTION
CENTER
MY INSPACE

Foreword

The Trials@Home initiative has explored the concept of decentralised clinical trials (DCTs) over the course of the last six years. The project brought public and private partners together to advance innovation and establish wide-ranging collaborations. Together we have created a robust ecosystem and challenged the status quo along the way.

We also created a set of in-depth recommendations covering the methodological, regulatory, ethical, operational and social aspects of DCTs. We can't wait to share these with you, and discuss the future of clinical trials.

In the meantime, explore our website to learn more about our final recommendations!

SCAN HERE TO EXPLORE OUR RECOMMENDATIONS

trialsathome.com





Detailed agenda

Welcome coffee and opening
08:30 - 09:15

Trials@Home key final recommendations
09:15 - 10:45

To kick off the day, project leads Kim Hawkins (Sanofi) and Mira Zuidgeest (University Medical Center Utrecht) will present the Trials@Home recommendations for decentralised clinical trials (DCTs). They will share the rationale behind these recommendations, explain who they are intended for, how they were developed, and how they can be applied in practice. Key highlights from the recommendations will also be discussed.

In the second part of the session, six panelists will take the stage. Each panelist has been closely involved in the Trials@Home work and will reflect on the recommendations they consider most impactful. This will be followed by an interactive Q&A with the audience. The panelists are Helga Gardarsdottir (Utrecht University), Sten Hanke (FH Joanneum, BBMRI-ERIC), Isla Mackenzie (University of Dundee), Megan Heath (Sanofi), Reamonn Madden (Novartis, and João Nabais (IDF Europe).

Coffee and poster gallery
10:45 - 11:15

Trials@Home deep dive

11:15 - 12:15

After a coffee break, we continue with short presentations by Trials@Home task leads, who will highlight in-depth research results from the full scope of Trials@Home.

The following topics will be addressed:

- Opportunities and challenges for DCTs in emerging markets – Pepijn Al (University Medical Center Utrecht)
- Do people prefer to participate in a clinical trial from home or at the trial site? – Julia Kopanz (University Medical Center Utrecht)
- Ethics and diversity in decentralized clinical trials – Tessa van Rijssel (University Medical Center Utrecht)
- Bringing the Trial to the Patient: Direct-to-Participant IMP Supply in Europe – Helga Gardarsdottir (Utrecht University)
- Greener trials? Evaluating the carbon impact of decentralisation in the RADIAL trial – Rebecca Barr (University of Dundee)
- A Technology Helpdesk System for Multi-Vendor Decentralized Clinical Trials – Sten Hanke (FH Joanneum, BBMRI-ERIC)
- How to effectively involve patient representatives in public-private consortia – Erik Werson (PEP)
- Economic insights into decentralised and hybrid clinical trials – Aniek Schouten (University Medical Center Utrecht)

The session will be moderated by Bart Lagerwaard (University Medical Center Utrecht) and Hamidou Traore (UCB) and the presentations will be followed by Q&A with the audience.

Lunch, networking, poster gallery and group photo

12:15 - 13:45

Impact in the DCT field

13:45 - 14:55

In this session, four panelists will share their reflections on the Trials@Home recommendations for DCTs. They will discuss what insights they gained, which opportunities they see for implementation, and what aspects surprised them most.

Unlike the morning session, this panel features experts from outside the consortium, offering fresh perspectives from across the DCT landscape. The panel includes representatives from regulatory bodies, patient advocacy, clinical research organizations, and site networks:

- Monique Al (CCMO, CTCG) – regulatory perspective
- Maria Dutarte (EUPATI) – patient advocacy
- Martine Dehlinger-Kremer (EUCROF) – clinical research organizations
- Martin Johnson (FutureMeds) – site networks

Their diverse viewpoints will enrich the discussion and help identify key priorities for the broader adoption of DCTs. The audience will be invited to participate in this conversation as well. The session will be moderated by Helga Gardarsdottir (Utrecht University) and Megan Heath (Sanofi).

Coffee and poster gallery

14:55 - 15:25

The future of DCTs

15:25 - 16:55

Opening the fourth theme of the day, Peter Arlett (European Medicines Agency) will deliver a keynote lecture exploring the future of clinical evidence. His talk will cover the place of DCTs, evolving legislation, emerging technologies such as AI, and a vision for the next decade of clinical research.

The keynote will be followed by a dynamic discussion, moderated by Sten Hanke and Isla Mackenzie, featuring five panelists from across the DCT ecosystem. These experts will talk about the opportunities, challenges, and priorities for the future of DCTs.

Throughout the session, the audience will have the opportunity to engage directly with the panelists via an open Q&A. The panelists are Peter Arlett (European Medicines Agency), Kit Roes (European Medicines Agency), Kai Langel (DEEP), Mira Zuidgeest (UMC Utrecht), Kim Hawkins (Sanofi).

Zooming in from the future of the field to the future of the initiative: what is next for Trials@Home? This is what Kim Hawkins (Sanofi) and Mira Zuidgeest (University Medical Center Utrecht) will present before handing the microphone to the last speaker of the day.

Niklas Blomberg (Innovative Health Initiative) will talk us through the outcomes and opportunities for public private partnerships in the field of clinical trials and share his vision on the future, including the role that IHI and IHI projects will play in advancing the field.

Wrap-up and drinks

16:55 - 18:00

TRIALS @HOME

Poster gallery

During the breaks, we invite you to explore the posters showcasing the diverse range of scientific research conducted within the project. These posters offer a unique opportunity to dive deeper into the work and connect with the researchers behind it.

The following posters will be displayed:

- Decentralized Trial Activities Reported in Publicly Available Clinical Trial Protocols
- A Systematic Review of Methods used to Conduct Decentralised Clinical Trials
- Learning from Decentralised Clinical Trial (DCT) experiences: a qualitative analysis of interviews with stakeholders
- Ethics review of Decentralized Clinical Trials (DCTs): Results of a mock ethics review
- Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective
- Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective
- What are digital literacy requirements for Decentralised Clinical Trials? A Delphi study to reach expert consensus
- Do people prefer to participate in a clinical trial from home? A discrete choice experiment in persons living with type 2 diabetes mellitus
- Patient preferences on decentralised clinical trial approaches: A focus group study to identify attributes
- RADIAL Study: A European Innovative Medicines Initiative Assessing a Decentralized Clinical Trial Approach in People with Type 2 Diabetes Treated with Basal Insulin


Purpose
Background
Results
Figure 1: Attribute preference weights
Figure 2: Relative attribute importance


5. CODE
Communication, dissemination & stake-holder engagement
- Technology
- Compliance
- PsychoSocial
- Organisational


What are digital literacy requirements for Decentralised Clinical Trials?
A Delphi study to reach expert consensus

Our speakers

Monique Al

Monique is currently special advisor at the Central Committee on Research Involving Human Subjects (CCMO) in The Netherlands. She is vice-chair of the Clinical Trial Coordination Group (CTCG) and co-chair of MedEthicsEU. Her background is Clinical Nutrition with a PhD in Human Biology. She has worked for several nutritional and pharmaceutical companies in the field of clinical research before she started in 2001 as a scientific staff member at the CCMO. She was part of the drafting team of the EU recommendation paper on decentralized elements in clinical trials published in December 2022.

Pepijn Al

Pepijn is a postdoctoral researcher working on research ethics at UMC Utrecht and LUMC. He obtained a PhD in philosophy from the University of Western Ontario with a dissertation on the ethics of innovative methods in trial participant recruitment. He has a strong interest in the ethics of trials and related issues, such as the ethics of various trial recruitment techniques; autonomy of trial participants; trust relationships between patient-participants, healthcare professionals, communities, and trial personnel; and equity, diversity, and inclusion in clinical trials. He is currently working on the qualitative research of the subproject on decentralized trials in emerging markets.

Peter Arlett

Peter is Head of the Data Analytics and Methods Taskforce at the European Medicines Agency. In this role he leads operations and transformation on clinical evidence at the EMA including clinical trials, real world evidence, safety reporting and data science including AI. He is Chair of the EMA Data Board, Co-Chair of the HMA-EMA Network Data Steering Group, Co-chair of the EMA AI Coordination Group, Co-chair of the Vaccine Monitoring Platform Steering Group, and Member of the ACT EU Steering Group. Prior to taking up this role in 2020, he held leadership roles within the EMA in the areas of pharmacovigilance, epidemiology, and risk management.

Prior to starting at EMA in 2008, Peter worked on new legislation and international collaboration for the European Commission, was the UK delegate to the European Committee for Human Medicinal Products, and was an assessor and manager at the UK's MHRA. He has a medical degree from University College London, and began his career as a hospital physician in Oxford and London.

Rebecca Barr

Rebecca is a Senior Research Manager at the University of Dundee, Scotland, with over 20 years of experience in academic clinical studies. She holds a PhD in Cardiovascular Science, an MSc in Pharmacology and a BSc in Pharmacology. Currently, Rebecca oversees multidisciplinary teams delivering complex clinical studies, with a keen focus on developing and implementing decentralised clinical trials. By integrating digital tools and remote methods, she aims to optimise recruitment, enhance accessibility, improve data quality and prioritise participant experience. As a former project manager of the ALL-HEART and TIME randomised controlled trials, she is committed to advancing innovative, patient-centred approaches in clinical research.

Niklas Blomberg

Niklas joined IHI in 2024, serving as Executive Director of Innovative Health Initiative JU. Prior to IHI he spent 10 years as the founding Director of for the European life science research data infrastructure ELIXIR (Cambridge UK) and 14 years with AstraZeneca. Niklas had undergraduate studies in biochemistry at University of Gothenburg, and a PhD in structural biology and bioinformatics from the European Molecular Biology Laboratory in Germany.

In the IHI Public-Private partnership Niklas enjoys the unique opportunity to bring together industry, academic and civil society across the healthcare sector - from pharmaceuticals and biotechnology to medical technology and big data – and drive projects that address public health needs, improve patients' lives, and boost the competitiveness of Europe's health industries.

Martine Dehlinger-Kremer

Martine brings over 30 years of experience in global clinical research, with a particular focus on global regulatory affairs, medical affairs, maternal-fetal medicine and pediatric leadership. She has been actively involved in advancing pediatric research, drug development, maternal-fetal medicine, and global regulatory strategies.

She served as Vice President of Scientific Affairs and Pediatric Subject Matter Expert at ICON PLC’s Center for Pediatric Clinical Development. As Co-Chair of ICON’s Maternal-Fetal Medicine Unit, she helped drive forward-thinking approaches in maternal-fetal care. Her career includes executive roles at global CROs and leadership in drug development across more than 40 countries.

She is also Chair of the Paediatric Working Group and President of EUCROF, an observer member of the Coordinating Group of Enpr-EMA, co-Chair of the Children’s Medicines Working Party, and Board Member of the European Forum for Good Clinical Practice. She also advises the International Children’s Advisory Network, contributes to the ACT EU Multistakeholder Platform and serves on the Trials@Home External Stakeholder Platform.

Sabine Dupont

Sabine is Policy and Strategy Director at IDFE. She has extensive communication and advocacy experience in the field of diabetes and life science/pharmaceutical arenas through her previous roles at the Global International Diabetes Federation and, prior to this, as Europe Director for the Society of Laboratory Automation and Screening, General Manager for the Alliance for Advanced Therapies and General Manager Europe for the International Society of Pharmaceutical Engineering. As well as her policy role, Sabine also leads patient engagement, communication and dissemination activities in all IDFE research projects, with a keen interest on ensuring that the needs of people living with diabetes are taken into account across all that matters to them – from identification of research needs, trial designs through to the final evaluation of medicines and technologies.

Maria Dutarte

Maria is the Executive Director of EUPATI, a non-profit multistakeholder organisation initially launched as an IMI project. Its core mission is to enhance patient involvement by providing information, education, and opportunities for collaboration throughout all aspects of the health innovation ecosystem. One of its core activities is the Patient Expert Training Programme on medicines' research & development process addressed to patients. It covers the entire lifecycle of medicines research and development, from design and execution of research projects and clinical trials to regulatory processes and Health Technology Assessment.

Maria has previously worked for the European AIDS Treatment, French National Research Center for Scientific Research, International AIDS Society, The Global Fund to Fight AIDS, Tuberculosis and Malaria and The International Foundation for Science. Her educational background is in International Education and Communications.

Helga Gardarsdottir

Helga is a Professor at Utrecht University and Scientific Director of the Center for Pharmacoepidemiology. She is also Adjunct Professor of Pharmacoepidemiology at the University of Iceland and serves as a Seconded National Expert in the Data Analytics and Methods Taskforce (RWE Workstream) at EMA.

Her primary interests include the generation and analysis of RWD on medicines to inform decision making, as well as assessing impact of drug regulation on safe and effective use in populations. She has led and participated in several international research projects including PROTECT, Trials@home and several EMA tendered studies on behalf of the EU Pharmacoepidemiology and Pharmacovigilance Research Network. She is the co-chair of the ENCePP steering group, co-led the Real-World Evidence Task Force of the International Society of Pharmacoepidemiology and is an associate editor of the journal 'Pharmacoepidemiology & Drug Safety'.

Sten Hanke

Sten is Associate Professor for Health Infrastructure at FH Joanneum, Scientific Stakeholder Manager at BBMRI-ERIC, and Associate Editor for Frontiers in Advanced Technologies for Medicine. He holds a Ph.D. in Medical Sciences from the Medical University of Vienna and an M.Sc. in Electrical and Computer Engineering from the Technical University of Dresden.

His previous positions include Scientific Coordinator at AIT Austrian Institute of Technology and Senior Researcher at the University of Geneva. He has led and contributed to 20+ EU-funded projects, with expertise in research infrastructure management and stakeholder engagement, biobanking and biomolecular resources, AI and machine learning applications in healthcare, biosignal processing and psychophysiological measurements, personal health systems and wearable technologies, cognitive support systems and dementia care, and medical device interoperability and standards.

Kim Hawkins

Kim has 30 years of experience managing all phases of the drug development process. Kim is currently the Global Head of Clinical Project Operations & Dossier Delivery, the team of clinical operations leads responsible for the management of all clinical programs and submission dossiers. Kim has a Bachelor's degree in Human Physiology and a Master's degree in Public Health.

Kim also leads projects focused around the evolving clinical trial model to build innovation and digital technology into our programs to further optimize clinical research for Sanofi and patients. In this role, Kim has led the integration of decentralized approaches into trials at Sanofi and is currently the co-lead for the IMI Trials@Home Project.

Megan Heath

Megan brings 25 years of experience in drug development to her role in Trials@Home. With expertise spanning all phases of clinical research, she is a leader in innovative clinical operations and serves on the EU ACT Multistakeholder Panel.

Currently serving as Head of Clinical Studies Units European Region in Sanofi's R&D division, Megan oversees country clinical operations across multiple therapeutic areas including Rare Disease, MS/Neurology, Immunology, and Oncology. Within Sanofi, she sponsors the SMILE initiative (Sanofi Making Investigator Lives Easier), a strategic program focused on reducing clinical site burden. Megan holds a PhD in Asthma Pharmacology from the University of Manchester and a Bachelor's degree in Pharmacology from Glasgow University.

Martin Johnson

Martin has a broad medical background, with specific training and expertise in clinical trials and research in multiple therapeutic areas. He has a particular interest in pain management and was RCGP representative for Chronic Pain for almost 20 years plus Vice President of the British Pain Society. He has been involved in various roles (sub investigator, PI, CI, Sponsor Medical Monitor and Medical Director/Senior Medical Director/CMO) in over 250 studies and 35+ years, working closely with academic groups and the industry in these fields.

Martin has a background of 29 years of General Practice combined with extensive Primary Care Research and Healthcare reorganisation. During the height of the pandemic he was part of the team that developed the world's first COVID Challenge model – one of the highlights of his research career. He has worked in a variety of clinical research organisations and at present work as UK Medical Director for FutureMeds Ltd. Research continues to motivate and fascinate Martin.

Julia Kopanz

Julia is a PhD candidate at the Department of Global Public Health & Bioethics at the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht in the Netherlands. She has a background in health and nursing sciences, and her PhD research focuses on patients' perspectives on decentralised clinical trial approaches. Julia is particularly interested in patients' motivations and preferences for taking part in clinical trials with different decentralisation levels. She identified key drivers for trial participation by conducting focus groups and elicited patients' preferences for trial participation using a discrete choice experiment. Her work is embedded within Trials@Home.

Bart Lagerwaard

Bart is an Assistant Professor at the Julius Center for Health Sciences and Primary Care, sub-department of Global Health, at the University Medical Center Utrecht. Trained in Molecular Nutrition and holding a PhD in Human Physiology with a focus on muscle ageing, his current research centres on clinical trial innovation and the integration of digital and decentralised approaches in health research. He served as the scientific coordinator of the RADIAL proof-of-concept trial within Trials@Home. RADIAL is one of Europe's first trials pioneering decentralised clinical studies in diabetes.

Kai Langel

Kai has been a pioneer in patient-facing solutions for clinical trials working with young innovative technology companies. Kai co-founded eClinicalHealth, the developers of the Clinpal – the world's first purpose-built decentralized clinical trial platform. Through his involvement in technical, operational and regulatory roles, he has gained deep understanding of broad aspects of the drug development process and the ecosystem behind it.

Kai combines his innovation mindset and nimble execution with several years of experience working at Johnson & Johnson Innovative Medicine R&D in clinical innovation as well as strategy and innovation in regulatory policy. Today, Kai leads DEEP Measures Oy as a Founder and CEO, having started this initiative within J&J with DEEP becoming an independent company in 2022. DEEP's core mission is to accelerate the adoption of harmonized digital measures of health to be transform the way human health is managed.

Isla Mackenzie

Isla is Professor of Cardiovascular Medicine, Director of MEMO Research and the Hypertension Research Centre, and Associate Dean for Research in the School of Medicine, University of Dundee, Dundee, UK. She is also an Honorary Consultant Physician at Ninewells Hospital, Dundee and contributes to the cardiovascular risk clinical service. She has led a number of decentralised or hybrid clinical trials as chief/principal investigator eg ALL-HEART, FAST, TIME. She is the academic lead of WP1 BEST in the IMI Trials@Home project on decentralised clinical trials. In 2018, she was awarded the Grahame-Smith Prize for Clinical Pharmacology by the British Pharmacological Society for outstanding contributions to research in clinical pharmacology.

Reamonn Madden

Reamonn works at Novartis in Global Clinical Operations Innovation to find ways to make it easier for sites and patients from all walks of life to take part in trials. One way to achieve this is by bringing the trial to the patient through Decentralized Clinical Trials (DCT) elements, which Reamonn has driven for over 5 years as lead of the Novartis OneDCT working group – a collaboration of more than 30 Global and 12 in-county members working to share knowledge, prevent silos and look for ways to push DCT elements further. This leverages his more than 10 years in trial operations as a study lead and data manager, and his participation in various cross-industry consortia.

Reamonn has a Masters degree from Bristol University, UK, in Chemistry and spent early years of his career in the laboratory inventing new medicines. Now he works on making sure there is equitable access to trials for new medicines.

João Nabais

João graduated in Technological Chemistry from the University of Lisbon and he holds a PhD in Chemistry from the University of Evora, where he works as Assistant Professor with Habilitation. He has published 52 papers in International Journals, participated in 15 R&D projects as Researcher and is the co-author of 3 patents. Actually, Joao is Vice-Rector of the University of Evora. João is a member of the Comprehensive Health Research Center and a consultant to the Portuguese Diabetes Association (APDP). He was Vice-President of the International Diabetes Federation and President of the International Diabetes Federation, European Region. He was also a member of the Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) of the European Medicines Agency. The interest in DCT is to move science into the next level and to contribute to the patients to get faster access to innovations.

Tessa van Rijssel

Tessa is a postdoctoral researcher in healthcare ethics at the Department of IQ Health, Radboud University Medical Center in Nijmegen, the Netherlands. She is also affiliated with Radboud University's interdisciplinary research hub on Digitalization and Society (iHub). With a background in both philosophy and psychology, her current research focuses on the ethics of health research and technological innovation in healthcare, particularly the ethics of data-intensive health research and AI. In addition, she is an ethicist in a local medical research ethics committee. Tessa completed her PhD on the ethical aspects of decentralized clinical trials at University Medical Center Utrecht, as part of the IMI Trials@Home consortium.

Kit Roes

Kit is Professor of Biostatistics at Radboud University Medical Center Nijmegen (Netherlands) and is chair of the Methodology Working Party of the European Medicines Agency. His research focuses on design and analysis of clinical trials, with an emphasis on innovative designs, rare diseases and bridging the gap between clinical trials and real-world evidence. His experience includes over 25 years in clinical research in the pharmaceutical industry and academic life sciences, serving as expert as well as in different (international) senior management positions.

Additional note: In my bio no details on DCTs specifically, but this includes amongst others contribution to the HMA-EMA Recommendations paper, experience during COVID with decentralizing primary endpoint assessments for rare neurological disorders and Q&As/papers/presentations on statistical aspects of decentralisation of assessments.

Aniek Schouten

Aniek completed a bachelor's in international economics & business and a master's in health economics & management. She has is a junior researcher in the Health Economic Evaluation team at UMC Utrecht and doing a part-time PhD on the methodology of conducting health economic evaluations alongside multinational trials.

Hamidou Traore

Hamidou is an Associate Director at UCB Biopharma with 17 years of experience in Regulatory Affairs and 7 years in Molecular Microbiology and Epidemiology. He holds a Master's and a PhD in Pharmaceutical Sciences from the Université Libre de Bruxelles.

His career spans the full lifecycle of drug development, from early clinical trials to centralised EU marketing authorisations, across therapeutic areas including neurology, oncology, respiratory, and infectious diseases. As regulatory co-lead of Trials@Home consortium, Hamidou played a central role in shaping Europe's regulatory and scientific understanding of DCTs, contributing to landmark publications on regulatory interactions, stakeholder perspectives, and operational learnings from RADIAL.

Erik Werson

Erik is a patient advocate for people with diabetes, contributing to IDF Europe's Type 2 Diabetes Platform and the Trials@Home Patient Expert Panel. He also works in information security and compliance as Program Manager at DUO and Training Manager at ARAMA TECH, and runs Werson BV, offering consultancy in compliance risk management and process improvement.

Mira Zuidgeest

Mira works as Associate Professor at the UMC Utrecht. Trained as pharmacist and epidemiologist, with a PhD in pharmacoepidemiology, her work focuses on clinical trial innovation, the interaction between methodology and operations, how RWE can be generated through interventional research, how we can centre trials around participants rather than sites, and the effects of trial approaches on diversity of participants. She is academic lead of the IMI Trials@Home project, board member of the GetReal Institute and member of the ACT-EU multistakeholder platform advisory group.

Venue

About the Spoorwegmuseum

The Railway Museum is a world-class museum right in the heart of Utrecht. As you will find out, the Railway Museum is more than just a fun day out for families; it is also a unique location for business events.

The Trials@Home Closing Event will take place in the Expo room. The Expo is a beautiful industrial space with the impressive Longmoor, the largest and heaviest steam locomotive in the Netherlands, and the famous blue sign of Utrecht Central Station as a unique backdrop.

Need a quiet area to work during the breaks? You can use the 'Bedrijfsschool' area (upstairs, opposite from the museum shop).



Interested in the museum?

As a guest at this event, you'll have free access to the Railway Museum between 10:00 – 17:00 hrs. We've planned an extra long lunch break. Why not combine networking with a look around the museum?

- Take a ride on the Steel Monsters rollercoaster: an adventurous ride on real rails in a cart through the dark! This is one of the most popular and surprising parts of the Railway Museum. Discover the secret of a very special attic and get to know the many professions that exist in the railways...
- Want something calmer? Visit The Great Discovery to travel back in time to 1839 and you'll see De Arend, the very first steam locomotive in the Netherlands! The gleaming train stands next to the ornately decorated platform at the d'Eenhonderd Roe station, ready and waiting to depart.
- More interested in what the future holds? Have a look at the Hyperloop, a prototype vacuum train which can reach speeds of more than 1000 kph. To promote the development of the Hyperloop, Elon Musk's SpaceX announced an international Hyperloop Competition in 2015. There were more than 2,000 entrants, and the prototype exposed in the museum- created by the Delft Hyperloop Team in the Netherlands – emerged as the winner.

WiFi

Free WiFi will be available throughout the day. Simply connect to "Spoorwegmuseum" (no password required).

Arrival Procedure & Luggage

At the entrance of the museum, museum staff will welcome you and direct you to the Expo room. The registration desk for this event is located at the entrance of the Expo room. Here, you will receive your name badge. Coats and luggage can be stored in the Expo room behind the Longmoor train. This room is reserved for the Trials@Home event and is not shared with museum visitors.

Photography & Communication

There will be a photographer present at this event, and room audio and video of the stage will be recorded during the sessions. The photos, audio and video will be used for internal and external dissemination (e.g., newsletters, social media, trialsathome.com, etc.).

When registering for this event, you have indicated whether you consent to having your image recorded and used for internal and external dissemination (e.g., newsletters, social media, the website, etc.). Individuals who did not consent, have been contacted via email regarding the practicalities. If you do not consent and did not receive such email, or if you wish to withdraw your consent, please contact trialsathome@umcutrecht.nl as soon as possible.

Utrecht

Public transportation

To get to the Railway Museum, take bus 4, 8, 28, 50, 55, 73, or 77 from Utrecht Central station and get off at the Stadsschouwburg bus stop. There are two bus stations on Utrecht Centraal: Centrumzijde and Jaarbeurszijde. Make sure to check where your bus departs! From busstop Stadsschouwburg, the Railway Museum is just a 10-15 minute walk. Find the next option, including walking route, on https://9292.nl/. There are approximately 8 buses per hour.

As an alternative, why not try the most typical Dutch mode of transport: the bike? You can rent a 'fiets' for under €5 per day. From Utrecht Central Station, it takes 8 minutes by bike to get to the museum. Check it out: https://www.ns.nl/en/door-to-door/ov-fiets

The Railway Museum is located in the city centre of Utrecht. Depending on where you depart (and Dutch weather...), you can also consider walking to the museum. From Utrecht Central Station to the Railway Museum, it takes about 20 minutes on foot.

The Railway Museum also has its own train station, called Utrecht Maliebaan. This station is only used during the opening hours of the museum. The first train leaves at 9:31 from Utrecht Central station, and the last train leaves at 17:10 from the museum. To use this train, you need a valid train ticket, the same as for any train. You can use an OV Chipkaart or check in with your debit card.

By car

When coming by car, enter: 'Johan van Oldenbarneveltlaan 1, Utrecht' for navigation. More details and directions are available here: https://www.spoorwegmuseum.nl/en/visit/directions/

Wondering if you can park your car at the Railway Museum? You can! Please be aware, however, that parking space is limited. A parking pass for the Railway Museum car park costs €12.00 (including VAT) and is valid for one visit to the museum. It is not possible to reserve a parking spot in advance. There are eight spots for charging electric cars and there are four spots for disabled. To get a ticket, park your car on the parking space and buy an exit ticket at the cash register between 10:00-17:00. For more information, visit https://www.spoorwegmuseum.nl/en/visit/parking/.

What to do in Utrecht

In the heart of the Netherlands, in het Groene Hart, you find Utrecht. And did you know that Utrecht is actually the Heart of Health? If you want to discover Utrecht and all the possibilities this city has to offer, visit https://www.discover-utrecht.com/. For a brief overview, this Visitor's Guide will provide you with some nice highlights and tips and tricks for Utrecht: https://slider.utrechtmarketing.nl/visitors-guide-utrecht/.



THANK YOU SO MUCH!

We are very glad you were able to join us for this amazing milestone!

GIVE US YOUR FEEDBACK

EXPLORE OUR RECOMMENDATIONS